Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.

MLA

O’Neal, Wesley T., et al. “Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.” Journal of the American College of Cardiology, vol. 72, no. 16, Oct. 2018, pp. 1913–22. EBSCOhost, https://doi.org/10.1016/j.jacc.2018.07.077.

APA

O’Neal, W. T., Claxton, J. S., Sandesara, P. B., MacLehose, R. F., Chen, L. Y., Bengtson, L. G. S., Chamberlain, A. M., Norby, F. L., Lutsey, P. L., & Alonso, A. (2018). Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer. Journal of the American College of Cardiology, 72(16), 1913–1922. https://doi.org/10.1016/j.jacc.2018.07.077

Chicago

O’Neal, Wesley T, J’Neka S Claxton, Pratik B Sandesara, Richard F MacLehose, Lin Y Chen, Lindsay G S Bengtson, Alanna M Chamberlain, Faye L Norby, Pamela L Lutsey, and Alvaro Alonso. 2018. “Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.” Journal of the American College of Cardiology 72 (16): 1913–22. doi:10.1016/j.jacc.2018.07.077.